
Zydus secures USFDA orphan drug tag for sickle cell therapy Desidustat
February 10, 2026
Zydus Lifesciences has received Orphan Drug Designation from the US Food and Drug Administration (USFDA) for Desidustat, its novel oral therapy being developed for the treatment of Sickle Cell Disease (SCD), the company said on Friday. The USFDA grants orphan








